Previous 10 | Next 10 |
Summary After years of losses, Legend Biotech’s new cancer drug Cavykti offers it a chance to finally start contributing revenue to its parent, Genscript Biotech. Some analysts believe Genscript may have become profitable last year, but also worry over its mounting R&D and sa...
Summary Legend Biotech and partner Johnson & Johnson announced positive topline results from the CARTITUDE-4 trial of Carvykti last week. Positive results were expected and the market was not impressed either as no data was mentioned in the press release. The two companies will ...
Summary HutchMed out-licensed global rights (ex-China) for a colorectal cancer therapy, fruquintinib, to Takeda Pharmaceutical in a deal worth up to $1.13 billion, including $400 million upfront. Guangzhou Akeso was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatm...
Legend Biotech ( NASDAQ: LEGN ) announced Friday that Carvykti, the CAR-T cell therapy that the company commercializes with Johnson & Johnson ( NYSE: JNJ ), met the primary endpoint in a Phase 3 trial for patients with multiple myeloma. The CARTITUDE-4 trial involved adult...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that CARTITUDE-4, the Phase 3 study evaluating CARVYKTI ® (ciltacabtagene autoleuce...
Legend Biotech ( NASDAQ: LEGN ) received a notice from Nasdaq for not being in compliance with the exchange's listing rules as the company failed to file an interim balance sheet and income statement for the quarter ended June 30, 2022 on Form 6-K with the Securities and Exchange Comm...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases today announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. ...
Legend Biotech ( NASDAQ: LEGN ) said on Monday that China's National Medical Products Administration (NMPA) accepted its new drug application (NDA) seeking approval for ciltacabtagene autoleucel (cilta-cel) to treat a type of blood cancer. The NDA was backed by data from a phase 2...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that China’s National Medical Products Administration (NMPA) has formally accepted it...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...